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Repair of lesions of the articular cartilage lining the joints remains a major clinical challenge. Surgical
interventions include osteochondral autograft transfer and microfracture. They can provide some relief of
symptoms to patients, but generally fail to durably repair the cartilage. Autologous chondrocyte im-
plantation has thus far shown the most promise for the durable repair of cartilage, with long-term
follow-up studies indicating improved structural and functional outcomes. However, disadvantages of
this technique include the need for additional surgery, availability of sufﬁcient chondrocytes for im-
plantation, and maintenance of their phenotype during culture-expansion. Mesenchymal stem cells offer
an attractive alternative cell-source for cartilage repair, due to their ease of isolation and amenability to
ex vivo expansion while retaining stem cell properties. Preclinical and clinical studies have demonstrated
the potential of mesenchymal stem cells to promote articular cartilage repair, but have also highlighted
several key challenges. Most notably, the quality and durability of the repair tissue, its resistance to
endochondral ossiﬁcation, and its effective integration with the surrounding host tissue. In addition,
challenges exist related to the heterogeneity of mesenchymal stem cell preparations and their quality-
control, as well as optimising the delivery method. Finally, as our knowledge of the cellular and mo-
lecular mechanisms underlying articular cartilage repair increases, promising studies are emerging
employing bioactive scaffolds or therapeutics that elicit an effective tissue repair response through
activation and mobilisation of endogenous stem and progenitor cells.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Traumatic lesions of the joint surface remain a major clinical
challenge, due mainly to the poor self-healing ability of articular
cartilage. If untreated, these joint surface lesions can lead to sec-
ondary osteoarthritis (OA). It is estimated that post-traumatic OA
represents 13% of knee OA and 73% of ankle OA1. In a prospective
study, it was reported that traumatic joint lesions in young adults
double the risk of developing knee OA2. Hence, symptomatic
chronic full-thickness defects of the knee joint surface require
intervention for symptom relief and to prevent possible evolution
towards OA. Tissue engineering and regenerative medicine offer
the potential for a long-term solution via biological repair or
replacement of the damaged joint tissues3. This review discusses
the current status of cell-based approaches to repair traumatic joint
surface lesions.. De Bari, Institute of Medical
een AB25 2ZD, UK. Tel: 44-
ofs), johnpjrocke@gmail.com
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s Research Society International. PCurrent therapeutic interventions
Osteochondral autograft transfer system (OATS) and mosaic-
plasty involve the use of osteochondral plugs from non-weight-
bearing regions of the joint to repair injured articular cartilage4. A
study investigating the outcomes of over 800 mosaicplasties per-
formed over a 10-year period showed promising results in tibial,
patello-femoral and femoral condyle lesions but also discovered
multiple cases of adverse events including the need for second-look
arthoscopies, painful haemarthrosis, and mild-to-severe degener-
ative change within the joint5. An alternative surgical procedure is
microfracture, which aims at creating a surgical communication
between the joint space and the subchondral bone marrow. The
theoretical basis for the cartilage repair is the release from the
marrow space of mesenchymal stem cells (MSCs) and progenitors,
which would then form a repair tissue. Signiﬁcant pain relief and
improved function of the glenohumeral joint, and improved func-
tion of the knee joint, were reported in case series of 16 and 72
participants, respectively6,7. While these procedures appear to
alleviate pain and improve mobility, neither of these surgical
techniques have been subjected to randomised, controlled trials,
and as such their true effectiveness for achieving durable cartilageublished by Elsevier Ltd. All rights reserved.
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pendent of the quality of the repair tissue, a ﬁbrocartilaginous
repair tissue may not sustain a long-lasting therapeutic effect
because of the high risk of secondary breakdown due to its poor
mechanical properties. Marrow stimulation techniques such as
microfracture promote a “callus-like” repair tissue, which can un-
dergo degeneration over time with the formation of scar-like
ﬁbrous tissue or be replaced with bone8,9. Indeed, patients failing
microfracture treatment do not seem to show a hyaline-like carti-
lage repair tissue10.
Autologous chondrocyte implantation (ACI)
ACI involves obtaining a cartilage biopsy from a healthy area of
the patient’s articular cartilage, isolating and culture-expanding the
chondrocytes, and implanting the culture-expanded chondrocytes
within the cartilage defect, traditionally under a periosteal ﬂap. ACI
was ﬁrst described in 1994 by Brittberg and colleagues, who re-
ported symptomatic relief in 14 out of 16 patients with lesions of
the femoral condyle at 2 years follow-up11. Since ACI was ﬁrst
approved by the US Food and Drug Administration in 1997, the
technique has evolved into second and third generation ACI with
the use of synthetic membranes and three-dimensional matrices12.
The recently coined third generation technique, or matrix-induced
ACI (MACI), involves the culture of the harvested autologous
chondrocytes onto a three-dimensional biocompatible scaffold,
which is subsequently implanted via either arthroscopy or open
surgery13.
Clinical trials have conﬁrmed the good clinical outcome of ACI,
but whether ACI is superior to other standard treatments in
controlled prospective clinical trials is somewhat controversial.
Superiority in terms of structural outcome was shown with ACI
over mosaicplasty14, while there was no clear difference in short-
term (2 years) structural or clinical outcome with microfracture15.
More recently, Saris et al. assessed 118 patients at 12 and 18months
following either ACI (using a characterised cell therapy product) or
microfracture. Clinical outcome was similar in both groups but ACI
was associated with increased structural repair16. At 5 years clinical
outcomes were again comparable. However, ACI was statistically
more effective in a subgroup of patients who had undergone the
procedures close to presentation of symptoms17. Results from long-
term follow-up studies are now beginning to be reported. At 10-
year follow-up, in a population of 100 patients with large joint le-
sions, the ACI procedure showed a lower failure rate (17% vs 55%)
and better functional outcome, compared to mosaicplasty18. Up to
20 years’ follow-up have demonstrated that ACI is an effective and
durable solution for the treatment of large joint surface lesions of
the knee joint19. A key question that now remains is whether ACI
intervention is effective in preventing secondary OA.
Nonetheless, ACI poses several challenges. Chondrocytes are
harvested from a cartilage biopsy of a low load-bearing area of the
same joint, thus requiring an additional surgical procedure. The
amount of healthy cartilage available for chondrocyte harvesting
can be limiting, and chondrocyte yields and in vitro proliferative
capacity decrease with age20, resulting in a limited number of cells
available for transplantation, especially in older patients. Further-
more, chondrocytes have a tendency to dedifferentiate during
culture-expansion to a ﬁbroblast-like phenotype21,22 and lose their
capacity to form stable hyaline cartilage in vivo23. After ACI,
remodelling and maturation of the cartilage repair tissue appear to
occur over time24. It is tempting to speculate that, under speciﬁc
conditions, in patients after ACI a regeneration process may occur
after an initial phase of repair, but this is likely to require an optimal
combination of high-quality chondrogenic cells and receptivity of
the joint environment. It is therefore not surprising that thephenotype of culture-expanded chondrocytes, as well as the time
between symptom onset and treatment, are important factors to
inﬂuence clinical and structural outcomes25. The use of chon-
drocytes expanded under conditions that preserve their cartilage-
forming potency and the phenotypic characteristics of articular
cartilage (resistant to vascularisation and replacement by bone)
may enhance potential for hyaline-like cartilage repair tissue for-
mation leading to remodelling and, ultimately, joint surface
regeneration25. The remodelling of the cartilage repair tissue is
likely to be complex and delicate, hence susceptible to failure
leading to the formation of a mechanically ineffective scar-like
repair tissue, a doorway to secondary OA. Indeed, variability in
structural outcome after ACI has been reported, with some patients
showing repair tissue consisting of poorly differentiated and dis-
organised ﬁbrocartilage26.
MSC-based cartilage repair
MSCs are considered an attractive alternative cell-source for
cartilage repair due to their relative ease of isolation, their
amenability to ex vivo expansion while retaining stem cell prop-
erties, and their ability to give rise to chondrocytes. MSCs were ﬁrst
isolated and characterised from bone marrow27e29. Since then,
MSCs have been isolated from most connective tissues30 including,
amongst others, periosteum31e33, synovium34, and adipose
tissue35.
Preclinical studies have demonstrated the potential for culture-
expanded MSCs to promote repair of cartilage and subchondral
bone and prevent secondary OA. In a study published almost 2
decades ago now, Wakitani et al. implanted either bone marrow or
periosteal MSCs suspended in a collagen gel into full-thickness
cartilage defects in the medial femoral condyle of rabbits.
Hyaline-like repair tissue quickly formed which was superior to the
ﬁbrous tissue formed in defects treated with MSC-free collagen
implants, although a progressive thinning and deterioration of the
articular cartilage was observed over time, with biomechanical
properties inferior to the native cartilage, and roughening of the
articular surface36. Murphy et al. showed in goats in which the
medial meniscus was excised and the anterior cruciate ligament
was resected, that intra-articular injection of MSCs suspended in a
sodium hyaluronan solution stimulated regeneration of the medial
meniscus and decreased development of secondary OA as seen in
untreated animals37.
Results of clinical case reports and small clinical case series
suggest that MSC therapy may improve cartilage repair38e40, but to
date, only one small controlled clinical trial of MSC therapy for
cartilage repair has been reported. Wakitani et al.41 implanted
autologous bone marrow MSCs suspended in a collagen gel into 12
patients with knee OA undergoing high tibial osteotomy and
covered the implanted cells with autologous periosteum. Another
12 patients underwent the same procedure but without MSCs. The
MSC-treated group demonstrated improved arthroscopic and his-
tological grading scores compared to the cell-free control group, as
assessed up to an average of 42 weeks after the procedure. How-
ever, the repair tissue still appeared inferior to the surrounding
native cartilage, with only 20e40% of cells showing a round to
polygonal shape similar to chondrocytes of hyaline cartilage, and
toluidine blue metachromasia mostly restricted to the middle/deep
zone with lack of staining in superﬁcial zone. Furthermore, there
was no signiﬁcant clinical improvement41. Similar histological re-
sults were reported in a case study by Kuroda et al38. Until results
from large, prospective, randomised, controlled clinical trials
become available, deﬁnitive conclusions regarding the clinical and
structural beneﬁts of MSC therapy for cartilage repair/regeneration
cannot be drawn. Clinical trials comparing ACI with autologous
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light on the suitability of MSCs to replace chondrocytes as cell
source for cartilage repair. Nejadnik et al.42 reported on clinical
outcomes of 72 patients who received either ACI or autologous
bone marrow-derived MSC implantation. Clinical scores were
similar between both groups up to 24 months after the procedure.
Histological assessment of the repair tissue 1 year after the pro-
cedure was shown for one patient, showing the presence of a
hyaline-like repair tissue, although full tissue morphology was
unclear and no comparison with repair tissue from an ACI-treated
patient was shown. Nevertheless, these data suggest that MSCs
could be a suitable alternative cell source to chondrocytes at least
on the basis on non-inferiority in terms of clinical outcomes42,
although longer-term follow-up and, ideally, more robust assess-
ment of structural outcome are needed to draw deﬁnitive
conclusions.
While preclinical and clinical studies have demonstrated the
potential of MSCs to promote articular cartilage repair and, at least
in some preclinical studies, decrease the development of secondary
OA, these studies have also highlighted several key challenges;
most notably, the quality and durability of the repair tissue, its
resistance to endochondral ossiﬁcation and replacement by bone
over time, and its effective integration with the surrounding host
tissue. In addition, challenges exist related to the heterogeneity of
MSC preparations and their quality-control, as well as optimising
the delivery method.
Regulating MSC differentiation and cartilage phenotype
Articular chondrocytes are nowwell-recognised as being able to
form stable cartilage in vivo that is resistant to vascular invasion,
calciﬁcation and endochondral ossiﬁcation23. These properties are
at least desirable, if not required, in a cellular product aiming at
articular cartilage repair/regeneration. The molecular basis of
chondrocyte stability, however, remains unknown.
Chondrogenic differentiation of MSCs in vitro using classical
micromass/pellet high cell density assays attempts to reproduce
the developmental chondrogenic limb anlage cascade of events.
However, it typically induces an “unnatural” differentiation
pathway resulting in concomitant expression of markers of hyaline
as well as ﬁbrous and hypertrophic cartilage43,44. Fibrous cartilage,
characterised by high levels of collagen type I, is inferior to hyaline
cartilage in mechanical properties, and is susceptible to degener-
ation and failure over time. Hypertrophic cartilage, characterised by
expression of collagen type X, matrix metalloproteinase-13 (MMP-
13), vascular endothelial growth factor (VEGF), alkaline phospha-
tase, and other hypertrophic chondrocyte markers normally found
in growth plate cartilage but not in stable articular cartilage, un-
dergoes mineralisation and remodelling by osteoclasts and osteo-
blasts in a process reminiscent of developmental endochondral
ossiﬁcation, leading to replacement of the cartilage by bone45.
Studies comparing donor-matched bovine MSCs and articular
chondrocytes for their cartilage-forming capacity in vitro using an
agarose hydrogel system and stimulation with transforming
growth factor beta (TGF-b) revealed that the amount and me-
chanical properties of the extracellular matrix produced by MSCs
were inferior to those produced by chondrocytes, and plateaued
with time, suggesting the diminished capacity is not the result of
delayed differentiation46e48. In addition, in contrast to chondrocyte
pellets, when in vitro MSC-derived cartilaginous tissues were
transplanted ectopically in mice, depending on culture conditions
and MSC type, they were either broken down and resorbed45,49,50,
or calciﬁed, invaded by vasculature and ultimately remodelled to
bone through a process mimicking endochondral ossiﬁca-
tion44,45,50,51. Although in vitro culture and ectopic implantationmay not necessarily reﬂect the outcome following orthotopic
transplantation susceptible to environmental cues, these studies
highlight important intrinsic differences between articular chon-
drocytes and MSCs in the stability of cartilage that is produced.
Uplift of the bone front at the expense of the overlying articular
cartilage has been observed in osteochondral repair by bone
marrow cells52, and this has its clinical counterpart in intra-lesional
osteophyte formation in patients after microfracture53. This phe-
nomenon appears to be less frequent in patients treated with ACI54,
suggesting that an imprinted memory of articular chondrocytes
could be sufﬁcient to limit the advancement of the bone front, thus
preserving the normal thickness of the repaired cartilage tissue.
While remodelling of the MSC-derived cartilaginous tissue to bone
may be ideal for bone repair through recapitulation of develop-
mental processes45,51, this is clearly undesirable for the durable
repair of articular cartilage. There is thus a need for improved
strategies to enhance cartilage properties and reduce ﬁbrous and
hypertrophic tissue formation.
Many pathways are involved in the regulation of chondrocyte
hypertrophy, including parathyroid hormone-related protein
(PTHrP)/Indian hedgehog (IHH), wingless/int (WNT)/b-catenin, and
TGF-b/sma and mad-related family (SMAD) pathways, converging
on runt-related transcription factor 2 (RUNX2) and myocyte
enhancer factor 2C (MEF2C) to drive expression of hypertrophic
genes. Modulation of these pathways to suppress hypertrophy of
MSC-derived cartilage-like tissues has been explored, either
directly for example by treatment with PTHrP55e57, or indirectly
through factors including hypoxia, co-culture with articular chon-
drocytes, epigenetic modulation, and biomaterial composition58.
Such studies have demonstrated that modulation of chondrogenic
hypertrophy is feasible, at least in vitro. Whether sustained sup-
pression of hypertrophy and maintenance of a stable cartilage
phenotype can be achieved in vivo using any of these approaches
remains to be determined.
The solution to the challenge of stable-cartilage formation may
come from the use of chondroprogenitors isolated from the artic-
ular cartilage itself59,60. By using a differential adhesion assay to
ﬁbronectin, the Archer lab has recently identiﬁed a population of
chondroprogenitors from human articular cartilage with the ability
to maintain chondrogenic potency upon extensive expansion, un-
like full-depth chondrocytes that lost this ability after only seven
population doublings. A proof-of-principle pilot study in a goat
model in vivo demonstrated the apparent non-inferiority of these
chondroprogenitors to form a cartilage-like repair tissue in a
chondral defect when compared with full-depth chondrocytes,
although both cell types resulted in repair tissue with a rough and
irregular surface appearance suggesting that also in this study, true
cartilage regeneration may not have been achieved61. Human
studies are now awaited.
Heterogeneity of MSCs between tissues
Bone marrow has been the most commonly used tissue for
extraction of MSCs and is currently regarded as the gold-standard
MSC source for musculoskeletal tissue engineering approaches. It
is not clear, however, whether bone marrow is the ideal source of
MSCs for the repair of articular cartilage. Several studies have
directly compared donor-matched MSCs from different tissues.
Overall, synovium-derived MSCs appear to have the greatest
chondrogenic ability in vitrowhen compared with MSCs from bone
marrow, periosteum, adipose tissue, infrapatellar fat pad, and/or
muscle, in humans50,62e64, rats65 and rabbits66. Following trans-
plantation into full-thickness cartilage defects in rabbits, bone
marrow, periosteal and synovial MSCs induced osteochondral
repair, while adipose and muscle-derived MSCs failed to repair or
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only compared the quantity of cartilaginous matrix produced
without comparing the formed tissue qualitatively or assessing its
stability, aspects which may have greater clinical relevance. In a
recent study by Vinardell et al., synovial and infrapatellar fat pad-
derived MSC chondrogenic pellets appeared to undergo ﬁbrous
dedifferentiation or resorption following ectopic implantation in
nude mice50, consistent with a previous study with synovial
MSCs49. In contrast, bone marrow MSCs showed increased type X
collagen expression and mineralisation, both in response to in vitro
hypertrophic culture conditions and following in vivo ectopic im-
plantation50, in line with other previous studies with bone marrow
MSCs44,45. Adipose-derived MSCs35, although considered an
attractive source of MSCs due to the large numbers of cells that can
be harvested with relatively little donor morbidity, do not seem to
be conducive for cartilage repair63,66,67. This may be related to their
lack of expression of TGF-b type I receptor and reduced expression
of bone morphogenetic protein (BMP)-2, BMP-4, and BMP-6, when
compared with bone marrow MSCs68. Infrapatellar fat pad-derived
MSCs, however, are more chondrogenic and appear similar in po-
tency and functionality to synovial MSCs50,63,67,69.
Such ﬁndings show that, despite similar phenotypic character-
istics, MSCs from different tissues show signiﬁcant functional het-
erogeneity, both in vitro and following in vivo transplantation. This
may reﬂect distinct physiological roles in their native tissues. Bone
marrow MSCs form an essential part of the bone marrow stroma,
supporting and regulating haematopoiesis through interactions
with haematopoietic stem cells70, as well as the sinusoidal
network71. In addition, they seem to function to continuously
replenish the local pool of short-lived osteoblasts72. In contrast,
MSCs in synovium may primarily function as a reservoir of stem
cells for the endogenous regeneration/repair of joint tissues,
including articular cartilage and menisci, although this remains to
be established. It is possible that imprinted embryonic memory
from distinct ontogeny paths is responsible for the variation in
biological properties of MSCs from different tissues following their
isolation, culture-expansion, and in vivo implantation, and possibly
also to some extent for their distinct endogenous functions in vivo.
Alternatively, epigenetic changes may be induced in MSCs ac-
cording to local environmental cues within their native tissues,
which could also be responsible for the observed heterogeneity of
MSCs from different tissues.
Heterogeneity of MSCs within tissues
In addition to the heterogeneity between MSCs from different
tissues, considerable heterogeneity exists between individual cells
isolated from the same tissue. Due to the lack of speciﬁc markers to
identify human MSCs, these cells are typically isolated based on
their plastic-adherence, and deﬁned retrospectively by phenotypic
marker expression and ability to differentiate into osteoblasts,
chondrocytes and adipocytes73. Therefore, MSC cultures are het-
erogeneous populations of cells that at the single-cell level show
signiﬁcant variability in potency33,74e76. On the one hand, this
heterogeneity may result in variability in clinical outcomes and
highlights the need for robust quality-control of cell preparations,
while on the other hand this raises the possibility of identifying and
purifying subpopulations of cells with improved potency.
The search for speciﬁc markers to purify MSCs prospectively has
mostly been explored in bone marrow. A key candidate marker for
MSC enrichment that has emerged is CD271, or low-afﬁnity nerve
growth factor receptor (LNGFR)77,78. The CD271bright population of
non-haematopoietic bonemarrowcells appears to contain all colony
forming cells78e80, although additional markers are likely required
in order to increase MSC purity81. One of these that has receivedattention is CD146 or melanoma cell adhesion molecule (MCAM)71.
Recent studies investigating expression of both CD271 and CD146 in
human bone marrow found CD146 to be expressed by a subpopu-
lation of CD271bright cells79,80. Both the CD271brightCD146þ and
CD271brightCD146 fractions contained colony forming cells that
expressed classical MSCmarkers, including CD73, CD90 and CD105,
and were capable of trilineage differentiation79,80. Tormin et al.79
further demonstrated that CD146 expression in vivo is restricted to
perivascular CD271-expressing cells while endosteal CD271-
expressing cells lacked CD146 expression, although whether the
cells identiﬁed invivoare clonogenic,multipotent cells remains tobe
proven. Interestingly, CD146 expression in culture was upregulated
in normoxia and downregulated under hypoxic conditions, sug-
gesting that CD146 expression by MSCs in vivo may be variable
depending on vicinity to the vasculature and local oxygen levels79,
although other mechanisms such as calcium-induced CD146 shed-
ding on cells close to the bone surface may contribute82. Whether
functional differences exist between CD271brightCD146þ and
CD271brightCD146 cells that would favour either one of these
populations for different therapeutic applications remains to be
clariﬁed.
Delivery method
In addition to the choice of cell populations, the deliverymethod
is also likely to impact on the success of MSC therapy, and many
different delivery systems have been explored. Most studies have
delivered the cells using a three-dimensional scaffold that is
implanted in the defect site, usually by means of an open surgical
procedure. Selection of the scaffold material is an important aspect
as it can provide topographical cues as well as chemotactic and
growth factors. Large joint surface defects not only affect the
articular cartilage but also the subchondral bone. The thinning of
the articular cartilage goes hand in hand with a thickening and
stiffening of the subchondral plate, making the cartilage more
susceptible to damage from shear forces. Treatment of large joint
surface defects should therefore aim to restore the entire osteo-
chondral unit, not simply the overlying cartilage. To this end,
several groups have developed multiphasic osteochondral scaf-
folds, to mimic osteochondral structures for guiding the repair of
both the cartilage and underlying bone, which have shown prom-
ising results in preclinical studies83. However, regional speciﬁcation
of transplanted MSCs to directly contribute to both articular carti-
lage and subchondral bone repair appears to take place in the
absence of multiphasic scaffolds, at least preclinically84, suggesting
that local environmental cues may be effective in guiding the repair
of, and integration with, the subchondral bone. A bigger challenge
appears to be stable lateral integration of newly-formed cartilage to
existing adjacent cartilage85. Several approaches have been
explored in in vitro or ectopic transplantation models to promote
integration of neocartilage with the surrounding cartilage, such as
pretreatment with matrix-degrading enzymes86,87, treatment with
an inhibitor of apoptosis to prevent chondrocyte death typically
occurring at wound edges88, or delivery of exogenous chondrocytes
to the cartilage interface suspended in a ﬁbrin glue89 or seeded
onto a collagen membrane90. How successful such approaches are
orthotopically, or indeed clinically, remains to be determined.
Cartilage repair through stimulation of endogenous stem cells
and reparative signalling pathways
It is generally thought that articular cartilage has little capacity
for intrinsic regeneration and repair, possibly due to a lack of blood
supply, low cell mobility due to surrounding matrix, and/or a
limited number of progenitor cells. Therefore, tissue engineering
Table I
Comparison of chondrocytes and mesenchymal stem cells for articular cartilage repair
Chondrocytes Mesenchymal stem cells
Advantages  Provide a “like for like” replacement for
degenerated cartilage
 Proven clinical safety and efﬁcacy
 Easy to isolate from various adult tissues
 Easy to culture-expand
 Anti-inﬂammatory as well as regeneration properties
 Amenable to one-stop ‘off-the-shelf’ procedure
Disadvantages  Need for invasive surgery to harvest cells
 Technically challenging to obtain sufﬁcient numbers
 Tendency to dedifferentiate during culture-expansion
 Tendency to give rise to hypertrophic cartilage susceptible
to calciﬁcation and endochondral ossiﬁcation
 Unreliability of cellular products due to heterogeneity and
lack of standardised bioprocessing
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exogenous cartilage tissue. In recent years, it has become increas-
ingly clear, however, that the actions of exogenously administered
MSCs go beyond their differentiation potential and the replacement
of cells lost due to injury or disease. In the study by Murphy et al.,
employing intra-articular injection of labelledMSCs in a goat model
of trauma-induced OA, it was observed that the injected, labelled
bone marrow MSCs did not engraft on the articular cartilage, and
only accounted for a minority of the chondrocytes in the regener-
ated meniscus37. In a more recent study, one day after intra-
articular injection of GFP-labelled adipose-derived MSCs in a
mouse model of OA, GFP-positive cells were found attached to
cruciate ligaments, as well as within the synovium, while at 5 days
after injection, virtually no GFP-positive cells were observed. Yet,
thickening of the synovial lining and formation of enthesophytes
were signiﬁcantly inhibited 42 days after OA induction when MSCs
were injected early (at day 7)91. Similarly, intraperitoneal injection
of MSCs prevented tissue destruction in the mouse model of
collagen-induced arthritis, even though injected MSCs were not
found to localise to the joints92.
Although the effects of MSCs for the prevention of OA and in-
ﬂammatory arthritis through the secretion of trophic factors may be
distinct from their ability to directly repair a tissue defect via cell
replacement, such ﬁndings have suggested that MSCs establish a
repair-conducivemicroenvironment, stimulating the recruitment of,
and tissue repair by, endogenous stem/progenitor cells. Taking this
one step further, this raises the possibility that we may be able to
designbioactive scaffoldsor therapeutics thatelicit aneffective tissue
repair response in the host through activation and mobilisation of
endogenous stem and progenitor cells without the need to admin-
ister exogenous cells. Such approacheswould be easier to implement
clinically and likely to encounter fewer regulatory hurdles.
Several studies have explored the use of scaffolds impregnated
with various chemotactic or differentiation factors. Lee et al.93
demonstrated that an acellular scaffold infused with TGF-b3-
absorbed collagen hydrogel was able to induce repair of the
entire articular surface, as well as the subchondral bone, of prox-
imal humeral condyles in rabbits, with biomechanical properties
close to that of native cartilage. However, whether the repair tissue
is of equivalent quality to native cartilage, and could be considered
regenerated tissue as the authors claim, is questionable judging by
the irregular and somewhat ﬁbrotic surface appearance of the
repair tissue93. Unfortunately, no histomorphological comparison
with native cartilage was presented. Nevertheless, the ﬁndings
from this proof-of-concept study raise the possibility that we may
be able to repair an entire joint surface, not just a focal defect in the
articular cartilage, through the stimulation of endogenous stem/
progenitor cells. More recently, Zhang et al.94 used stromal cell-
derived factor-1 (SDF-1) to promote migration of endogenous
stem/progenitor cells to the defect site. Repair was achieved in
partial-thickness defects of the articular cartilage in rabbit knee
joints when a collagen I scaffold with SDF-1 was implanted,
whereas defects failed to heal if left untreated or implanted withcollagen I alone. Endogenous cells expressing MSC markers were
detected along the cartilage surface and within the defect94. This
interesting study shows the potential to stimulate cartilage repair
by using chemotactic factors that recruit endogenous stem/pro-
genitor cells to the defect site. However, the repair tissue that had
ﬁlled the defect at 6 weeks post-treatment was positive for colla-
gens type I and X, indicative of a ﬁbrous/hypertrophic tissue94. In
this regard, it should be noted that SDF-1 is not only a chemotactic
factor, but also promotes chondrocyte hypertrophy through its
interaction with C-X-C chemokine receptor type 4 (CXCR4) on
chondrocytes and upregulation of RUNX2 expression, which is part
of the cascade of endochondral ossiﬁcation in the growth plate95,96.
Hence, SDF-1 may not represent the ideal chemotactic factor. In
addition, the recruitment of stem/progenitor cells to the defect site
alonemay not be sufﬁcient to give rise to stable cartilage repair, and
may need to be combined with factors regulating MSC differenti-
ation and induction of a stable chondrocyte phenotype.
While the factors regulating chondrocyte phenotype in the
growth plate are now well-understood, the factors responsible for
the formation and maintenance of stable articular cartilage are still
poorly deﬁned. Recently, Johnson et al. identiﬁed the small mole-
cule kartogenin as a stimulator of chondrogenic differentiation of
bone marrowMSCs, acting via a novel biological pathway involving
binding to ﬁlamin A and disrupting its interaction with the tran-
scription factor core-binding factor b subunit (CBFb)97. Intra-
articular injection of kartogenin was found to protect against OA
development in mice, and it was suggested that kartogenin may
modulate endogenous stem cells to confer a regenerative/repair
effect and/or a protective effect. Kartogenin may also protect
existing chondrocytes against the pathological effects of proin-
ﬂammatory cytokines97. This study thus shows the potential to
identify new biological pathways and small molecules that pro-
mote joint homoeostasis and protect against OA.
Conclusions and future perspective
Arthroplasty remains the ultimate intervention for end-stage
OA patients with chronic pain and functional disability. However,
for pre-OA joint surface lesions and early OA, cell-based therapies
are increasingly becoming available. The type of cell-based thera-
peutic interventionwill likely depend on the clinical indication and
on factors such as size and depth of the lesion, health status of the
surrounding articular cartilage and of the other joint tissues, and
will range from ACI (with chondrocytes, MSCs or other stem cell
types) to the implantation of cell-free scaffolds loaded with
regenerative biomolecules.
MSCs represent promising types of adult stem cells for joint sur-
face repair, offering both advantages and disadvantages compared
with autologous chondrocytes (Table I). Besides their capacity to
differentiate into chondrocytes and osteoblasts, they play a role as
cellularmodulators to endorse tissue repair via secretion of bioactive
molecules. Intriguingly, the MSC capacity to activate endogenous
reparative mechanisms appears to be dependent on the degree of
A.J. Roelofs et al. / Osteoarthritis and Cartilage 21 (2013) 892e900 897stemness98, highlighting the importance of consistent bioprocessing
of the MSC products to deliver to patients. There is therefore a
requirement for cell potency assessment in order to standardise
manufacturing and ensure clinical effectiveness.
The availability of large batches of “off-the-shelf” quality-
controlled allogeneic MSC populations will enhance consistency
of treatments while reducing costs; it will also eliminate the need
for two operations and enable large-scale production. Alternatively,
several devices are becoming available to purify from bone marrow
cell populations containing MSCs, to be then implanted straight-
away into the patient’s cartilage lesion in a one-stop procedure.
Minimally manipulated MSC preparations are expected to simplify
autologous procedures as well as the regulatory paths.
Current therapeutic approaches to joint surface defects pursue
long-lasting, pain-free joint function by promoting the formation of
a repair tissue that integrates with the surrounding tissues and
displays a cell phenotype, extracellular matrix composition and
tissue durability that are similar to articular cartilage. Regenerative
medicine aims at biological regeneration of the damaged joint
tissues to fully restore joint homoeostasis, regeneration referring to
the replacement of damaged tissue with an identical tissue such
that both anatomy and function are fully restored. Regeneration
could follow the initial phase of repair through long-lasting
remodelling, as occurs in highly regenerative tissues such as the
skin. There is some evidence to suggest that cartilage remodelling
and, possibly, regeneration can occur in at least some patients
undergoing ACI24. Whether regeneration may be achieved using
MSC implantation is at present unclear.
A fascinating prospect is the pharmacological targeting, by using
drugs, of the native stem cells and related reparative signalling
pathways in the joint in order to repair or even regenerate the
damaged joint tissues. In this regard, there is evidence that, under
speciﬁc conditions, the joint surface has healing potential as re-
ported in animal models93,99 and in humans100, but the mecha-
nisms remain to be elucidated. Hence, the identiﬁcation and
characterisation of the stem cell niches in the joint and the inves-
tigation of how signals at the niche sites are orchestrated towards
joint homoeostasis, remodelling and repair are important areas of
research. The lack of speciﬁc markers to identify MSCs in their
native tissues in vivo has for a long time hampered studies aimed at
understanding the roles of MSCs during tissue homoeostasis,
remodelling and repair. However, with the discovery of novel
markers70e72,79 and alternative approaches to identify functional
MSCs in vivo101, we are beginning to elucidate the in vivo location of
MSCs and characterise the niches that regulate MSC fate and
function. The cell-based biological therapies of the joint tissues
appear to be just at the beginning of their journey but have the
potential to beneﬁt millions of patients worldwide.
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